Sorrento, Under Shadow Of Chapter 11, Looks To Move BTK Inhibitor Into Phase III

 
• By Alaric DeArment
Sorrento announced results from its Phase IIa trial of abivertinib in marginal zone lymphoma • Source: Shutterstock

More from Clinical Trials

More from R&D